Gilead Sciences (GILD) Tops Q3 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021 4:02 PM EDT2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter
Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.
This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Veklury is making a significant impact as the COVID-19 pandemic continues... More
